Table 1 Clinical data summary.
From: Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas
Clinical features | All samples (n = 67) |
|---|---|
Gender | |
Male | 41 (61.2%) |
Female | 26 (38.8%) |
Age at diagnosis (years old) | |
Mean ± SD | 39.3 ± 12.2 |
Median | 38.0 |
Tumour location: lobular involvement | |
Unilobular | 52 (77.6%) |
Multilobular | 8 (11.9%) |
Involvement of non-lobular areas | 7 (10.4%) |
Tumour location: lobe | |
Frontal lobe | 48 (71.6%) |
Temporal lobe | 16 (23.9%) |
Parietal lobe | 4 (6.0%) |
Occipital lobe | 5 (7.5%) |
Others | 2 (3.0%) |
Tumour enhancement pattern | |
Enhanced | 37 (55.2%) |
Not enhanced | 5 (7.5%) |
Unknown | 25 (37.3%) |
Operation | |
Gross total resection | 56 (83.6%) |
Subtotal resection | 9 (13.4%) |
Biopsy | 1 (1.5%) |
Unknown | 1 (1.5%) |
Adjuvant therapy | |
No adjuvant therapy | 11 (16.4%) |
Chemotherapy only | 0 (0%) |
Radiotherapy only | 2 (3.0%) |
Chemotherapy and radiotherapy | 50 (74.6%) |
Unknown | 4 (6.0%) |
Current status | |
Dead | 40 (59.7%) |
Alive | 24 (35.8%) |
Unknown | 3 (4.5%) |
Overall survival (months, Kaplan–Meier) | |
Median (95% CI) | 39.4 (24.6–54.2) |
2-year survival | 64.1% |
5-year survival | 30.8% |
